Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Phase I study of remimazolam for general anesthesia

Next Previous
X
Search
Trial Profile

A Phase I study of remimazolam for general anesthesia

Status: Planning
Phase of Trial: Phase I

Latest Information Update: 25 May 2018

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Remimazolam (Primary)
  • Indications General anaesthesia
  • Focus Adverse reactions

    • Most Recent Events

    • 17 May 2018 According to a PAION media release, this trial is expected to start in the second half of 2018 which can be expected to be the only necessary outstanding trial for filing for market approval in Europe based on the Scientific Advice obtained from the European Medicines Agency (EMA) in January 2018.
    • 23 Mar 2017 New trial record
    • 16 Mar 2017 According to a PAION media release, this trial will determine the number of patients required for a EU Phase III study (see profile 259255). Company expects to initiate this trial in 2017.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top